
Modern Methods in Drug Discovery

Aims of this course:

- comprehensive knowledge about all processes in the *drug discovery pipeline*
- in particular in silico methods of drug design



flow of information in a drug discovery pipeline



Covered by this lecture

Drug Discovery Today

Related topics not covered by this lecture

medicinal chemistry organic synthesis biopharmaceutical aspects (tissue models, non-oral administration) clinical aspects molecular modelling theory homology modelling theory docking basics and applications computational chemistry genome, proteome, metabolome bioethics and patent law



Required knowledge

Use of tools for sequence analysis, e.g. BLAST, CLUSTALW Use of visualizing tools, e.g. BALL, VMD, SPDBV, JMOL

recommended courses:

Softwarewerkzeuge der Bioinformatik Computational Chemistry Bioinformatics I + II

Actual applications during the excerices and homework:


multiple sequence alignment, homology in sequences simple homology modelling protein-ligand interactions

SMILES and SMARTS notation of chemical structures using SMARTS with Open Babel


substance database queries (PubChem, ChEMBL,...

What is drug discovery?

rational and targeted search for new drugs



typical targets (I)




contribution to the human genome and marketed drugs



typical targets (II)

drug targets by biochemical class



Fractional content of marketed drugs according to their biochemical targets

data: Hopkins & Groom, Nat.Rev.Drug.Disc. 1 (2002) 727

preliminary schedule (lectures)

- Introduction, overview, recap of chemical structures
- 2. typical diseases
- properties of drugs and their mode of action
- Substance databases and bioisosteric compounds
- 5. QSAR, statistics and descriptors
- 6. ADME models
- 7. metabolism and toxicology

- 8. target identification, animal models
- 9. cytochrome P450, polymorphisms, transporters
- 10. more complex diseases malaria, obesity
- 11. in silico prediction of molecular properties
- current trends,
 disease vs. lifestyle drugs,
 doping

preliminary schedule (exercises)

Biweekly in the CIP-Pool (building E 2.1 room 003) computer account and access card required

- chemical structures of drugs
- enzyme-ligand interactions, analysis of .pdb files
- substance databases and SMARTS queries
- QSAR, statistics and descriptor handling
- ortholog targets in model organisms
- further online tools



Compound Databases

existing substance libraries

ACD >100,000 chemicals

World Drug Index 58,000 compounds

USAN <10,000 in clinical trial

virtual library ≈100,000 compounds

commercial

company, in house


PubChem > 3,000,000 compounds NCBI

ChEMBL > 1,213,000 compounds EMBL

ZINC >73,126,243 compounds UCSF

academic








Investment per new chemical entity: >500,000 \$ New chemical entities per year: ca. 15

Methods of Combinatorial Synthesis for High Throughput Screening (HTS)

$$R1$$
 $R2$
 H
 H
 $R3$
 $R4$
 $R3$
 $R4$
 $R3$
 $R4$
 $R3$
 $R4$
 $R4$
 $R4$
 $R3$
 $R4$
 $R4$
 $R5$
 $R4$
 $R4$
 $R5$
 $R5$
 $R4$
 $R6$
 $R7$
 $R8$
 $R8$
 $R9$
 $R1$
 $R1$
 $R1$
 $R3$
 $R1$
 $R3$




Selection of compounds for High Throughput Screening (HTS)



Predictive ADME

Absorption
Distribution
Metabolism
Elimination


Pharmacokinetic Bioavailability






From the pipeline until the commerical launch

For each actual marketed drug (new chemical enitity, NCE) there have been more than 1000 substances that underwent screened in vitro. Without the use of available computer-based ADMET filters, this number would be even larger.




Nature Reviews | Drug Discovery

Why is the prediction of ADME parameters that important?



Reasons that lead to failure or withdrawl of a potential drug

pharmacokinetics and bioavailability




(Some) descriptors based on molecular properties used to predict ADME properties

logP water/octanol partitioning coefficient

Lipinski's rule of five topological indices polar surface area similary / dissimilarity

1st Lecture



QSAR quantitative structure activity relationship QSPR quantitative structure property rel.



metabolism

(bio-)chemical reactions of xenobiotics in the body

First pass effect:

Extensive metabolization of mainly lipophilic molecules, such with MW>500, or those that have a specific affinity to certain transporters, during the first passage through the liver

Phase I:

Oxidation, reduction and hydrolysis → esp. cytochrome P450 enzymes

Phase II:

Conjugation with small molecules (e.g. glutamine)

Phase III:

elimination by transporters



cytochrome P450 enzymes

Flavin monooxygenase isoenzme

Alcohol dehydrogenase


Aldehyde oxidase

Monoamine dehydrogenase (MAO)


Redoxactivity is enabled by a iron-containing porphyrin in the active site

Drug-R +
$$O_2$$
 $\xrightarrow{\text{CYP}}$ Drug-OR + H_2 O NADPH NADP





cytochrome P450 gene families



Modern Methods in Drug Discovery WS14/15

cytochrome P450 polymorphism

"Every human is (more or less) different"

Determination of the phenotype by the actual activity or the amount of the expressed enzyme.

In contrast, the genotype is determined by the individual DNA sequence.


Thus, the same genotype enables several different phenotypes

According to their metabolic activity of CYP there is a classification into normal (*extensive metabolizer*), weak (*poor metabolizer*), und accelerated (*ultra-rapid metabolizer*) metabolism.

Lit: K. Nagata et al. Drug Metabol. Pharmacokin 3 (2002) 167

genotyping of CYP P450 alleles

By using immobilized, synthetic copies of P450 nucleotides, the Affymetrix company (USA) has developed mircoarrays (gene chips) that allow the identification of all clinically relevant alleles.



Modern Methods in Drug Discovery WS14/15

Image of hybridized probe array

Prediction of molecular properties (I)

The keynote of rational drug design

The general question is:

What is the connection between the biological space (activity) and the chemical space (structure)?

How are we able to make structure-based prediction?

- → QSAR and QSRP, regression analysis
- → decision trees, machine learning algorithms
- → other statistical methods



Prediction of molecular properties (II)

What are molecular properties?


molecular weight MW (from the sum formula $C_{12}H_{11}N_3O_2$) melting point boiling point vapour pressure solubility (in water) charge dipole moment polarizability ionization potential electrostatic potential

Directly computable from the electronic wave function of a molecule

observables


BBB-model with 12 descriptors

Descriptors mainly from QM calculations: electrostatic surface, principal components of molecular geometry, H-bond properties



Lit: M. Hutter *J.Comput.-Aided.Mol.Des.* **17** (2003) 415. Modern Methods in Drug Discovery WS14/15

Cycle of optimization in the drug discovery pipeline



Source: D.K. Agrafiotis et al. Nature. Rev. Drug. Discov. 1 (2002) 337.

Accompanying books and further reading (I)

Andrew R. Leach*
Molecular Modelling. Principles and Applications
2nd edition, Prentice Hall, 2001


Rolf Knippers*
Molekulare Genetik
8. Auflage, Thieme, 2001


The Merck Index*

13th edition, Merck & CO., Inc., 2001


J.M. Berg, L. Stryer*
Biochemie, Spektrum Verlag
Biochemistry, W.H. Freeman & Co Ltd.

*Available in the "Semesterapparat"











Accompanying books and further reading (II)

Gerhard Klebe*
Wirkstoffdesign
2. Auflage, Spektrum Akad. Verlag, 2009

C.A. Orengo, D.T. Jones, J.M. Thornton*
Bioinformatics
Genes, Proteins & Computers
1st ed., Bios Scientific Publishers, 2003

Wirkstoffdesign
Entwurf und Wirkung
von Arzneistoffen


202

3.Andage

Systemen



A.R. Leach, V. Gillet* An Introduction to Chemoinformatics revised ed., Springer, 2007





*Available in the "Semesterapparat"



Further hands-on tools

Molecular model sets / Molekülbaukasten





Commerically available at various price ranges

General remark: The lecturer does not endorse any of the mentioned books/software/products. Enquiries are welcome.





Other useful software to make nice pictures

Chemical structures and other objects:
C-Design 3.0f
Windows-Platform

Protein structures:
PyMOL
www.pymol.org
Linux, Mac OS X, Windows







Requirements to obtain the certificate and the credit points

- 1. 50% of all accomplishable points from the home work. Two thirds (66.7%) of all assignments (ca. 6) must be returned. The assignments have to be handed in until the beginning of the next exercise unit.
- 2. 50% of all accomplishable points from the final exam taking place at the end of the lecture period. If necessary, repeated (written) exam or oral exam.




1st assignment (I)

Refer to a prescription medicine of your own choice

Write down the active ingridient

Try to find out its molecular structure:

http://pubchem.ncbi.nlm.nih.gov/













PubMed	Entrez	Structure	GenBank	PubChem	Help
--------	--------	-----------	---------	---------	------

Compound Summary:





1st assignment (III)



Medical Subject Annotations: (Total: 11) 2

Display: Next 1 | All

🚵 Aspirin

The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)

Show MeSH Tree Structure

Pharmacological Action:

Anti-Inflammatory Agents, Non-Steroidal Fibrinolytic Agents Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors

Explain why the medicine has a completely different name compared to the actual substance.

Try to find out some information about its molecular target:

e.g. using Wikipedia

Representation of chemical structures (I)

The valence electrons of the atoms are pairwise grouped together

Lewis structures reflect covalent bonds between atoms in a molecule



Representation of chemical structures (II)

(electron) lone pairs are often not shown for clarity

octet rule and hypervalent atoms

$$H-N$$
 $H-N$ $H-N$ $H-N$ $H-C$

Equal bond lengths!




Representation of chemical structures (III)

Also carbon atoms are often omitted

Corners and end of lines denote carbon atoms saturated with the appropriate number of hydrogen atoms

Representation of chemical structures (IV)

Stereochemistry




Solid wedges denote atoms in front of the plane, dashed wedges denote atoms behind

Four different substituents at a carbon atom cause chirality



Representation of chemical structures (V)

Particular for more complex molecules, these structural drawings provide more clarity than a picture of an actual 3D representation does.



Exercise: Construct this molecule using a molecular model set. Specify the chiral carbon atoms.

Bond distances and bond dissociation energies (I)


bond distance [Å] D_o [kJ/mol] (homolytic cleavage) H-H0.742432 C-H 1.09 ± 0.01 411 ± 7 C-C1.54 345 C=C 1.34 - 1.40* 602 ± 21 *aromatic bond C≡C 1.20 835 305 C-N 1.47 longer C=N 1.35 615 C≡N 1.16 887 Н He Li Be B O F С Ν C-O 1.43 358 longer, Na Mg Al Si C=O 1.20 526 Ca Ga Ge As Se Br Kr Rb Sr In Sn Sb Te I Xn C-Si 318 1.85 Cs Ba TI Pb Bi Po At Rn C-P 1.84 264 C-S Adapted from: J.E.Huheey 1.82 272 *Inorganic Chemistry*, Wiley. C=S 1.60 577 ± 21

Bond distances and bond dissociation energies (II)

bond	distance [Å]	D _o [kJ/mol]	
C-F	1.35	485	
C-CI	1.77	327	
C–Br	1.94	285	
C-I	2.14	213	
C–H	1.09	411 non-p	olar hydrogen
O–H	0.96	459	polar hydrogens,
N–H	1.01	386 ± 8	exchangable in
S-H	1.34	363 ± 5	polar solvents
N-N	1.45	247 ± 13	reason:
N=N	1.25	418	N, O, and S are more
N-O	1.40	201	electronegative than C;
N=O	1.21	607	heterolytic cleavage
P-O	1.63	≈335	that leads to ions
P=O	≈1.50	≈544	

Bond angles (I)

Strongly dependend on the hybridization




The C–C σ -bond is formed by overlap of the 1s orbitals

These are hybrizided atomic orbitals. Do not confuse with molecular orbitals (=linear combination of atomic orbitals)

Molecular Orbitals

MO = linear combination of atomic orbitals (LCAO)


 π -bond of ethylene $H_2C=CH_2$



The two combinations usually result in one bonding and one anti-bonding MO

Bond angles (II)

Extreme deviations from ideal bond angles




gives rise to strain energy in small rings

→ problems in force fields. More than one atom type per hybridization needed.


Chiral atoms

Further elements showing chirality/stereochemistry the lone pair behaves like a substituent



Furthermore: As, Si, ..., compounds with transition elements, esp. octahedral metal complexes


Isomers



Source: enhanced from wikipedia

Exercise: Which kind of computational method(s) allow(s) to calculate differences in energy between the respective isomers?

Is stereochemistry important?



Data from 1982: Böhm, Klebe & Kubinyi, Wirkstoffdesign